Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2001 1
2002 1
2003 3
2004 5
2005 6
2006 5
2007 4
2008 8
2009 7
2010 4
2011 2
2012 4
2013 2
2014 6
2015 4
2016 2
2017 4
2018 8
2019 14
2020 12
2021 9
2022 4
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Selective PP2A Enhancement through Biased Heterotrimer Stabilization.
Leonard D, Huang W, Izadmehr S, O'Connor CM, Wiredja DD, Wang Z, Zaware N, Chen Y, Schlatzer DM, Kiselar J, Vasireddi N, Schüchner S, Perl AL, Galsky MD, Xu W, Brautigan DL, Ogris E, Taylor DJ, Narla G. Leonard D, et al. Among authors: narla g. Cell. 2020 Apr 30;181(3):688-701.e16. doi: 10.1016/j.cell.2020.03.038. Epub 2020 Apr 20. Cell. 2020. PMID: 32315618 Free PMC article.
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J. Kauko O, et al. Among authors: narla g. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi: 10.1126/scitranslmed.aaq1093. Sci Transl Med. 2018. PMID: 30021885 Free PMC article.
Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation.
Peris I, Romero-Murillo S, Martínez-Balsalobre E, Farrington CC, Arriazu E, Marcotegui N, Jiménez-Muñoz M, Alburquerque-Prieto C, Torres-López A, Fresquet V, Martínez-Climent JA, Mateos MC, Cayuela ML, Narla G, Odero MD, Vicente C. Peris I, et al. Among authors: narla g. Blood. 2023 Mar 2;141(9):1047-1059. doi: 10.1182/blood.2022016466. Blood. 2023. PMID: 36455198 Free PMC article.
Therapeutic targeting of PP2A.
O'Connor CM, Perl A, Leonard D, Sangodkar J, Narla G. O'Connor CM, et al. Among authors: narla g. Int J Biochem Cell Biol. 2018 Mar;96:182-193. doi: 10.1016/j.biocel.2017.10.008. Epub 2017 Oct 26. Int J Biochem Cell Biol. 2018. PMID: 29107183 Free PMC article. Review.
Regulation and role of the PP2A-B56 holoenzyme family in cancer.
Peris I, Romero-Murillo S, Vicente C, Narla G, Odero MD. Peris I, et al. Among authors: narla g. Biochim Biophys Acta Rev Cancer. 2023 Sep;1878(5):188953. doi: 10.1016/j.bbcan.2023.188953. Epub 2023 Jul 10. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37437699 Free article. Review.
Targeting PP2A in cancer: Combination therapies.
Mazhar S, Taylor SE, Sangodkar J, Narla G. Mazhar S, et al. Among authors: narla g. Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):51-63. doi: 10.1016/j.bbamcr.2018.08.020. Epub 2018 Sep 1. Biochim Biophys Acta Mol Cell Res. 2019. PMID: 30401535 Free PMC article. Review.
Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.
Rasool RU, O'Connor CM, Das CK, Alhusayan M, Verma BK, Islam S, Frohner IE, Deng Q, Mitchell-Velasquez E, Sangodkar J, Ahmed A, Linauer S, Mudrak I, Rainey J, Zawacki KP, Suhan TK, Callahan CG, Rebernick R, Natesan R, Siddiqui J, Sauter G, Thomas D, Wang S, Taylor DJ, Simon R, Cieslik M, Chinnaiyan AM, Busino L, Ogris E, Narla G, Asangani IA. Rasool RU, et al. Among authors: narla g. Nat Commun. 2023 Aug 29;14(1):5253. doi: 10.1038/s41467-023-40760-6. Nat Commun. 2023. PMID: 37644036 Free PMC article.
110 results